查找临床试验
已按「多发性硬化」检索，对应国际通用词 multiple sclerosis
共找到 30 项正在招募的试验（在中国／港澳台设有中心）
数据更新于 23:03，每 5 分钟自动同步BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
China
年龄 18 Years – 65 Years
Peking University People's Hospital
A Study to Evaluate the Preliminary Efficacy and Safety of Terfenadine in Patients With Relapsing-Remitting Multiple Sclerosis
China
年龄 18 Years – 65 Years
Chuan Qin
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
United States、Belgium、Brazil、China、Italy 等 7 国
年龄 18 Years – 60 Years
Sanofi
Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis
Taiwan
年龄 20 Years – 100 Years
Novartis Pharmaceuticals
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
United States、Argentina、Australia、Austria、Belgium 等 12 国
年龄 18 Years – 65 Years
Novartis Pharmaceuticals
This is an Early Exploratory Study to Assess the Tolerability and Safety of GC012F in Patients With Multiple Sclerosis
China
年龄 18 Years – 不限
Daishi Tian
CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
China
年龄 18 Years – 70 Years
Tongji Hospital
Clinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE)
China
年龄 16 Years – 75 Years
Beijing Tiantan Hospital
Safety and Efficacy of S103 Cells in Progressive/Refractory Multiple Sclerosis
China
年龄 18 Years – 75 Years
Xijing Hospital
Biomarkers in Autoimmune Disease of Nervous System
China
年龄 18 Years – 不限
Tongji Hospital
Cohort Study on Neuroimmune Diseases in the Reproductive Age
China
年龄 20 Years – 55 Years
Third Affiliated Hospital, Sun Yat-Sen University
CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease
China
年龄 3 Years – 不限
The Children's Hospital of Zhejiang University School of Medicine